MedTrace Logo

The National Myelodysplastic Syndromes (MDS) Study

NCT02775383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2115

Last updated 2026-02-03

No results posted yet for this study

Summary

Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.

Conditions

  • Myelodysplastic Syndromes (MDS)

Interventions

OTHER

Therapeutic

Observational Study

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Mikkael Sekeres, MD, MS · University of Miami

  • Amy DeZern, MD, MHS · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-13
Primary Completion
2025-07-31
Completion
2025-12-31

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775383 on ClinicalTrials.gov